Adaptin Bio (APTN) Common Equity (2022 - 2026)

Adaptin Bio's Common Equity history runs 5 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Common Equity fell 201.74% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$1.8 million (down 201.74% YoY), while the FY2025 annual figure was -$1.5 million, up 63.67% from the prior year.
• Common Equity came in at -$1.8 million for Q1 2026 at Adaptin Bio, down from -$1.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 million in Q1 2025 to a low of -$4.1 million in Q4 2024.
• A 5-year average of -$990960.8 and a median of -$929318.5 in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 5865.06% in 2024 and jumped 232.52% in 2025, its largest moves.
• Adaptin Bio's Common Equity stood at -$27304.0 in 2022, then tumbled by 3480.28% to -$977559.0 in 2023, then tumbled by 319.42% to -$4.1 million in 2024, then soared by 63.67% to -$1.5 million in 2025, then fell by 19.21% to -$1.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$1.8 million, -$1.5 million, and -$881078.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison